Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$18.45 USD

18.45
7,100,133

+0.01 (0.05%)

Updated Nov 1, 2024 04:00 PM ET

Pre-Market: $18.54 +0.09 (0.49%) 9:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lilly (LLY) Q4 Earnings and Sales Top Estimates, Stock Up

by Zacks Equity Research

Eli Lilly's (LLY) Q4 earnings and sales beat estimates. Shares rise in pre-market trading.

Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)

by Zacks Equity Research

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258

by Zacks Equity Research

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

J&J's (JNJ) Q4 Earnings Surpass Estimates, Sales Fall Short

by Zacks Equity Research

J&J (JNJ) comes up with mixed fourth-quarter 2019 results.

Novartis (NVS) Gets Approval for MS Drug Mayzent in Europe

by Zacks Equity Research

Novartis' (NVS) MS drug, Mayzent, obtains approval in Europe for the treatment of adult patients with secondary progressive multiple sclerosis.

Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe

by Zacks Equity Research

Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.

J&J's $8B Jury Award in Risperdal Case Cut to $6.8M by Judge

by Zacks Equity Research

A Philadelphia judge slashes J&J's (JNJ) punitive damages in a lawsuit, which claims that the company did not warm men that they could grow breasts by using its antipsychotic drug, Risperdal.

Endo Up on Opioid Abuse Settlement Agreement With Oklahoma

by Zacks Equity Research

Endo (ENDP) settles an ongoing opioid-abuse litigation issue with the state of Oklahoma for $8.75 million.

Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study

by Zacks Equity Research

Axsome's (AXSM) migraine drug meets two regulatory, co-primary endpoints in a phase III study.

Indrajit Bandyopadhyay headshot

Will J&J be Able to Overcome Its Legal Troubles in 2020?

by Indrajit Bandyopadhyay

Here we discuss the growth potential of J&J's (JNJ) stock in 2020.

Is Mylan (MYL) Doomed to Witness a Terrible 2020 Too?

by Zacks Equity Research

As Mylan (MYL) remained plagued with challenges in 2019, we take an insight into whether or not, the next year holds any promise for the company.

Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy

by Zacks Equity Research

Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.

Teva Pharmaceutical Industries Ltd. (TEVA) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $9.97, moving +1.73% from the previous trading session.

Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up

by Zacks Equity Research

Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.

J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders

by Zacks Equity Research

J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.

Mylan (MYL) Launches Herceptin Biosimilar Ogivri in the US

by Zacks Equity Research

Mylan (MYL) launches Ogivri, a biosimilar of Roche's blockbuster breast cancer drug, Herceptin (trastuzumab), in the United States.

Kinjel Shah headshot

Fed Reportedly Opens Criminal Investigation on Opioid Makers

by Kinjel Shah

Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.

Indrajit Bandyopadhyay headshot

Generic Drugmakers Gain as Price-Fixing Probe Nears an End

by Indrajit Bandyopadhyay

Shares of generic drugmakers rose on Monday on a possible end to the persistent price-fixing probe.

Endo's (ENDP) BLA for Cellulite Treatment Accepted by FDA

by Zacks Equity Research

The FDA accepts Endo's (ENDP) BLA for CCH for the treatment of cellulite in the buttocks.

Jazz's (JAZZ) Sleep Drug Sunosi Nears Approval in Europe

by Zacks Equity Research

Jazz's (JAZZ) sleep drug, Sunosi, which is under review in Europe, receives recommendation for approval from the CHMP.

Is Teva Pharmaceutical Industries Ltd. (TEVA) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase

by Zacks Equity Research

Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.

Kinjel Shah headshot

5 Low Price-to-Book Stocks to Buy in November

by Kinjel Shah

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

Teva (TEVA) Q3 Earnings Miss, Sales Top Estimates, Stock Up

by Zacks Equity Research

Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. Shares rise in pre-market trading.

Mylan's (MYL) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Mylan's (MYL) earnings beat estimates but sales miss the same in the third quarter of 2019. The company updates guidance for 2019.